DEAR ABBY: After decades of research, I’m thrilled with the recent major progress being made in treatments for people who already have symptoms of Alzheimer’s disease. I’m hoping that, one day, we will be able to prevent people from developing memory impairment and dementia.
Brain changes, including the buildup of a toxic protein into amyloid plaques, begin up to 20 years before a person notices any symptoms. This “asymptomatic” stage may be the perfect time to test treatments aiming to delay or prevent symptoms before they begin.
This is why we are conducting the AHEAD Study, an investigational trial of lecanemab, an FDA-approved medication for mild cognitive impairment and mild dementia due to Alzheimer’s disease. The AHEAD Study is testing whether starting lecanemab in those with amyloid plaques BEFORE symptoms start can help prevent cognitive decline.
